Cancer therapies increasingly rely on understanding not only tumor biology but also the immune response of individual patients. This has made human immune cell models, including peripheral blood mononuclear cells (PBMCs), valuable tools in oncology research.
Utilizing peripheral blood mononuclear cells, or PBMCs for short, is one of the modern approaches to oncology research. Hundreds of laboratories buy PBMCs for thousands of immunology studies because these primary human cells represent an accessible sample of the immune system. Technicians use them for disease modeling, including cancer immunology.
Why PBMCs Are Used in Disease Modeling
PBMCs, contrary to single-cell-type preparations, are a lot more complex. They contain several cells, including:
- T cells;
- B cells;
- NK cells;
- monocytes.
When these immune populations are studied together, scientists can still access the common cell-to-cell interactions and cytokine networks for their laboratory processes. Additionally, longitudinal sampling from the same donor can help researchers compare immune profiles before and after treatment exposure.
Current State of Oncological Research
Unfortunately, not all oncological research has proven to be effective. The treatments used on patients have yielded different results. Although the existence of research activities shows undoubted progress in the cause.
For example, lung cancer can be divided into two types: non-small cell and small cell. The therapies used on the patient are also based on the cancer cell appearance and growth. Chemotherapy and immunotherapy used on lung cancer patients have evolved, revolutionizing standard care and strengthening the body while it fights against diseases, but it’s still not enough.
Some patients respond extremely well to the combination, while others don’t have any effects. Among lung cancer patients, PD-L1 expression remains an important biomarker for selecting patients for some immunotherapies, but additional biomarkers are needed to improve treatment prediction. PBMC profiling is one promising approach for identifying immune signatures associated with treatment response.
Role of PBMCs in Cancer Immunology
In many cancer patients, biopsy material is hard to obtain. This procedure is invasive and sometimes can be ineffective when capturing the dynamic nature of immune responses. PBMC analysis can complement tumor biopsy data by providing information about systemic immune responses.
This alternative is a useful tool in biomarker discovery. These white blood cells include other immune cells like T cells and NK cells while staying accessible: laboratories can purchase various isolated PBMCs from providers like Preci. They have a lot of potential to predict immune system reactions to treatments, including DDR inhibitors, as well as identify immune-related biomarkers such as CXCL10 and CCL5 expression patterns, as well as immune signatures associated with treatment response.
PBMCs — Next Step in Oncology Research
Despite being the leading cause of death, cancer still doesn’t have a treatment that would work effectively for all patients. In some cases, like lung cancer, it’s hard to do a biopsy to see if the therapy is working, but PBMCs allow for a non-invasive, practical approach. It’s a reliable and accessible approach for studying systemic immune responses.
